Halmos, B.; Burke, T.; Kalyvas, C.; Insinga, R.; Vandormael, K.; Frederickson, A.; Piperdi, B.
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC. Cancers 2020, 12, 3648.
https://doi.org/10.3390/cancers12123648
AMA Style
Halmos B, Burke T, Kalyvas C, Insinga R, Vandormael K, Frederickson A, Piperdi B.
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC. Cancers. 2020; 12(12):3648.
https://doi.org/10.3390/cancers12123648
Chicago/Turabian Style
Halmos, Balazs, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, and Bilal Piperdi.
2020. "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" Cancers 12, no. 12: 3648.
https://doi.org/10.3390/cancers12123648
APA Style
Halmos, B., Burke, T., Kalyvas, C., Insinga, R., Vandormael, K., Frederickson, A., & Piperdi, B.
(2020). A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC. Cancers, 12(12), 3648.
https://doi.org/10.3390/cancers12123648